Korean J Hematol 2005; 40(1):
Published online March 30, 2005
https://doi.org/10.5045/kjh.2005.40.1.8
© The Korean Society of Hematology
허대석, 백지연, 박숙련, 최인실, 김상일, 김동완, 김지현, 윤성수, 박선양, 김병국, 김노경, 허대석
서울대학교 의과대학 내과학교실
Background: An angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of lymphoma, accounting for only 1 to 2% of studies on non-Hodgkin's lymphomas. Because of the rarity of this disease, most studies have been small, including cases of various T-cell Non-Hodgkin's Lymphoma (T-NHL). Those patients diagnosed as AITL, during the last 8 years at a single institution (Seoul National University Hospital), were retrospectively analyzed to determine the clinical features and treatment outcomes of AITL.
Methods: All 24 of the patients diagnosed with AITL between February 1995 and February 2003 were included in this retrospective review.
Results:The predominant characteristics of the population were: median age 62 years (range, 32∼81); M/F=18/6; nodal involvement 24/24 (100%); extranodal involvement, particularly bone marrow 16/20 (80%); skin involvement 6/24 (25%); B-symptoms 18/24 (75%) and advanced disease (stages III and IV) in 20/24 (83%). Twenty-three of the 24 patients received combination chemotherapy, with 8/23 (35%) of patients obtaining a CR. The median CR duration was 18.1 months. With a median follow-up of 40.9 months, the 5-year OS rate was 28%, with median survival of 8.7 months. According to a univariate analysis, an elevated LDH showed a tendency to negatively influence the survival.
Conclusion: The prognosis of AITL is poor compared to other NHL, with a low CR rate and short CR duration and OS. From our data, the CR rate after first- or second-line chemotherapy were low (35%), compared with those previously described in Western reports.
Keywords Angioimmunoblastic, T-cell lymphoma, Clinical features, Prognosis, Treatment
Korean J Hematol 2005; 40(1): 8-14
Published online March 30, 2005 https://doi.org/10.5045/kjh.2005.40.1.8
Copyright © The Korean Society of Hematology.
허대석, 백지연, 박숙련, 최인실, 김상일, 김동완, 김지현, 윤성수, 박선양, 김병국, 김노경, 허대석
서울대학교 의과대학 내과학교실
Dae Seog Heo, Ji Yeon Baek, Sook Ryun Park, In Sil Choi, Sang, Il Kim, Dong, Wan Kim, Jee Hyun Kim, Sung, Soo Yoon, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim, Dae Seog Heo
Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Background: An angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of lymphoma, accounting for only 1 to 2% of studies on non-Hodgkin's lymphomas. Because of the rarity of this disease, most studies have been small, including cases of various T-cell Non-Hodgkin's Lymphoma (T-NHL). Those patients diagnosed as AITL, during the last 8 years at a single institution (Seoul National University Hospital), were retrospectively analyzed to determine the clinical features and treatment outcomes of AITL.
Methods: All 24 of the patients diagnosed with AITL between February 1995 and February 2003 were included in this retrospective review.
Results:The predominant characteristics of the population were: median age 62 years (range, 32∼81); M/F=18/6; nodal involvement 24/24 (100%); extranodal involvement, particularly bone marrow 16/20 (80%); skin involvement 6/24 (25%); B-symptoms 18/24 (75%) and advanced disease (stages III and IV) in 20/24 (83%). Twenty-three of the 24 patients received combination chemotherapy, with 8/23 (35%) of patients obtaining a CR. The median CR duration was 18.1 months. With a median follow-up of 40.9 months, the 5-year OS rate was 28%, with median survival of 8.7 months. According to a univariate analysis, an elevated LDH showed a tendency to negatively influence the survival.
Conclusion: The prognosis of AITL is poor compared to other NHL, with a low CR rate and short CR duration and OS. From our data, the CR rate after first- or second-line chemotherapy were low (35%), compared with those previously described in Western reports.
Keywords: Angioimmunoblastic, T-cell lymphoma, Clinical features, Prognosis, Treatment
Sung-Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang-Ki Min, Dok Hyun Yoon, Sung-Soo Yoon, Je-Jung Lee, Chae Moon Hong, Ka-Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok Do, Yeung-Chul Mun, Sung-Soo Park, Young Hoon Park, Ho Jin Shin, Hyeon-Seok Eom, Sang Eun Yoon, Sang Mee Hwang, Won Sik Lee, Myung-won Lee, Jun Ho Yi, Ji Yun Lee, Ji Hyun Lee, Ho Sup Lee, Sung-Nam Lim, Jihyang Lim, Ho-Young Yhim, Yoon Hwan Chang, Jae-Cheol Jo, Jinhyun Cho, Hyungwoo Cho, Yoon Seok Choi, Hee jeong Cho, Ari Ahn, Jong Han Choi, Hyun Jung Kim and Kihyun Kim
Blood Res 2025; 60():Hyewon Lee
Blood Res 2023; 58(S1): S66-S82Hyery Kim
Blood Res 2020; 55(S1): S5-S13